| Ytd | 31.77% | |
| 1y | 133.72% |
| Open | 244.77 | Prev Close | 244.77 | Low | 237.64 | High | 247.64 | Mkt Cap | 12.38B |
| Vol | 757.95K | Avg Vol | 898.99K | EPS | -3.73 | P/E | N/A | Forward P/E | 40.81 |
| Beta | 0.60 | Short Ratio | 4.99 | Inst. Own | 76.52% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-03 | 50-d Avg | 227.38 | 200-d Avg | 172.83 | 1yr Est | 276.47 |
In this week's edition of InnovationRx, we look at Axsome's growing pipeline, HistoSonics innovative
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatm
NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceu
TD Cowen analyst Joseph Thome maintains Axsome Therapeutics (NASDAQ:AXSM) with a Buy and raises t
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatm
Axsome Therapeutics, Inc. (NASDAQ:AXSM) (Axsome), a biopharmaceutical company leading a new era in t